🏥Fujifilm and Takeda announce collaboration to develop regenerative medicine therapies using cardiomyocytes derived from iPSC.

By IPS, Medical science

🏥Fujifilm and Takeda announce collaboration to develop regenerative medicine therapies using cardiomyocytes derived from iPSC.

FUJIFILM Corporation (“Fujifilm”, President: Kenji Sukeno) and Takeda Pharmaceutical Company Ltd., (“Takeda”, CEO: Christophe Weber) today announced a collaboration to develop regenerative medicine therapies using cardiomyocytes derived from iPSC for the treatment of heart failure.

Fujifilm Global

http://www.fujifilm.com/news/n180208.html

Fujifilm and Takeda Announce Collaboration to Develop Regenerative Medicine Therapies using Cardiomyocytes Derived from iPSC

https://www.takeda.com/newsroom/newsreleases/2018/fujifilm-and-takeda-announce-collaboration-to-develop-regenerative-medicine-therapies-using-cardiomyocytes-derived-from-ipsc/

More from tokioX :

  1. Kyoto Univ: Discovered ALS drug candidates: the drug bosutinib：
  2. Kyoto Univ: Providing “clinical IPS cells” overseas: Korean venture company
  3. Kyoto University: Identifies genes related to Alzheimer’s disease with iPS:
  4. Kyoto University: Reproduce intractable disease ALS with iPS cells: Therapeutic drug “Bosutinib”
  5. Kyoto University: Successful production of mature cardiomyocytes with iPS: Troponin protein
  6. Kyoto University: Providing iPS cells to Novo Nordisk: Macrophage research
  7. Kyoto University: Granted iPS cell license to Avery: Cardiomyocyte manufacturing method